Summary
Pfizer Inc.'s 2011 Form 10-K highlights a year of significant strategic shifts and ongoing challenges in the pharmaceutical industry. The company focused on streamlining its operations, evidenced by the sale of its Capsugel business and the exploration of strategic alternatives for its Animal Health and Nutrition segments. Despite a slight decline in biopharmaceutical revenues year-over-year, largely due to patent expirations of key products like Lipitor in the U.S. and Europe, Pfizer demonstrated resilience through strong performance in products such as Lyrica and the Prevnar franchise, as well as favorable foreign exchange impacts. The company's significant investment in research and development continues, albeit with a strategic realignment to focus on core therapeutic areas to enhance productivity and value. Pfizer also navigated the evolving regulatory landscape, including the ongoing implementation of the Affordable Care Act in the U.S., and faced continued pricing pressures in international markets. The report underscores Pfizer's commitment to innovation, operational efficiency, and adapting to a dynamic global healthcare environment.
Financial Highlights
54 data points| Revenue | $61.03B |
| Cost of Revenue | $12.50B |
| Gross Profit | $48.53B |
| SG&A Expenses | $17.58B |
| Operating Income | $7.82B |
| Interest Expense | $1.68B |
| Net Income | $10.01B |
| EPS (Basic) | $1.28 |
| EPS (Diluted) | $1.27 |
| Shares Outstanding (Basic) | 7.82B |
| Shares Outstanding (Diluted) | 7.87B |
Key Highlights
- 1Biopharmaceutical revenues saw a 1% decrease in 2011 compared to 2010, primarily due to loss of exclusivity for key drugs like Lipitor, Effexor, and Protonix.
- 2The company completed the sale of its Capsugel business for approximately $2.4 billion in cash.
- 3Pfizer is exploring strategic alternatives for its Animal Health and Nutrition businesses, potentially including spin-offs or sales, aiming to create shareholder value and enable a more focused organization.
- 4Research and Development expenses remained substantial at $9.1 billion in 2011, with a strategic focus on five high-priority areas and efforts to improve innovation and productivity.
- 5International operations accounted for 60% of total revenues in 2011, with significant contributions from emerging markets, though the company faces ongoing pricing pressures in these regions.
- 6The company experienced a favorable impact of foreign exchange, which increased revenues and net income in many countries.
- 7Pfizer is actively managing the impact of the Affordable Care Act (ACA) in the U.S., which includes changes in Medicaid rebates, discounts on branded drugs, and potential impacts from the Independent Payment Advisory Board (IPAB).